Herbert I Hurwitz


Ontology type: schema:Person     


Person Info

NAME

Herbert I

SURNAME

Hurwitz

Publications in SciGraph latest 50 shown

  • 2018-12 Genetic variation determines VEGF-A plasma levels in cancer patients in SCIENTIFIC REPORTS
  • 2018-12 Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2018-08 Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies in INVESTIGATIONAL NEW DRUGS
  • 2018-04 A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2018-02 Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2017-03 Phase I study of pazopanib plus TH-302 in advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-05 Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-05 Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study in SUPPORTIVE CARE IN CANCER
  • 2015-04 Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-02 A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-12 An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer in INVESTIGATIONAL NEW DRUGS
  • 2014-12 A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-10 A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2014-10 Effects of the combination of TRC105 and bevacizumab on endothelial cell biology in INVESTIGATIONAL NEW DRUGS
  • 2014-08 Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2014-05 Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-04 Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer in INVESTIGATIONAL NEW DRUGS
  • 2014-01 Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach? in CURRENT ONCOLOGY REPORTS
  • 2013-12 Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer in CURRENT COLORECTAL CANCER REPORTS
  • 2013-12 The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors in BMC CANCER
  • 2013-06 Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2013-01 Targeted therapies: Ziv-aflibercept: binding to more than VEGF-A—does more matter? in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2012-08 Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-07 A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-05 Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy in ANNALS OF SURGICAL ONCOLOGY
  • 2011-12 Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-02 Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-02 A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-02 Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study in BRITISH JOURNAL OF CANCER
  • 2010-05 Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2009-01 Multiagent Chemotherapy for Isolated Colorectal Liver Metastases: A Single-centered Retrospective Study in JOURNAL OF GASTROINTESTINAL SURGERY
  • 2008-08 The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2008 VEGF Inhibition for Cancer Therapy in MOLECULAR TARGETING IN ONCOLOGY
  • 2007-05 Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2007-02-13 Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer? in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2007-01 A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2005-03 Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer in ANNALS OF SURGICAL ONCOLOGY
  • 2004-02 Effects of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy in ANNALS OF SURGICAL ONCOLOGY
  • 2004-02 Prognostic significance of histologic response to preoperative chemoradiation for pancreatic cancer in ANNALS OF SURGICAL ONCOLOGY
  • 2002-08 The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer in JOURNAL OF GASTROINTESTINAL CANCER
  • 2002-07 Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2001-12 Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival in ANNALS OF SURGICAL ONCOLOGY
  • 2001-12 Staging of pancreatic cancer before and after neoadjuvant chemoradiation in JOURNAL OF GASTROINTESTINAL SURGERY
  • 2001-12 Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas in ANNALS OF SURGICAL ONCOLOGY
  • 1999-01 Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas in ANNALS OF SURGICAL ONCOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.189509.c", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.430503.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.213910.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16753.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.42505.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.250942.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.65499.37", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.492957.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.26790.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.67105.35", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411097.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.26009.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10698.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410513.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417570.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5963.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.423294.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414316.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.266102.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.25879.31", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413696.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.241116.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.66875.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.14925.3b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410711.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.19006.3e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.51462.34", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.477623.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415302.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.492893.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414179.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4367.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412807.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418158.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419513.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418019.5", 
            "type": "Organization"
          }
        ], 
        "familyName": "Hurwitz", 
        "givenName": "Herbert I", 
        "id": "sg:person.01242177577.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:52", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_591.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01242177577.68'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01242177577.68'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01242177577.68'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01242177577.68'


     

    This table displays all metadata directly associated to this object as RDF triples.

    88 TRIPLES      10 PREDICATES      47 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01242177577.68 schema:affiliation N2d3dc3ea35e14f6c9e885a56cd10444a
    2 https://www.grid.ac/institutes/grid.10698.36
    3 https://www.grid.ac/institutes/grid.14925.3b
    4 https://www.grid.ac/institutes/grid.16753.36
    5 https://www.grid.ac/institutes/grid.19006.3e
    6 https://www.grid.ac/institutes/grid.213910.8
    7 https://www.grid.ac/institutes/grid.241116.1
    8 https://www.grid.ac/institutes/grid.250942.8
    9 https://www.grid.ac/institutes/grid.25879.31
    10 https://www.grid.ac/institutes/grid.26009.3d
    11 https://www.grid.ac/institutes/grid.266102.1
    12 https://www.grid.ac/institutes/grid.26790.3a
    13 https://www.grid.ac/institutes/grid.410513.2
    14 https://www.grid.ac/institutes/grid.410569.f
    15 https://www.grid.ac/institutes/grid.410711.2
    16 https://www.grid.ac/institutes/grid.411097.a
    17 https://www.grid.ac/institutes/grid.412807.8
    18 https://www.grid.ac/institutes/grid.413696.f
    19 https://www.grid.ac/institutes/grid.414179.e
    20 https://www.grid.ac/institutes/grid.414316.5
    21 https://www.grid.ac/institutes/grid.415302.1
    22 https://www.grid.ac/institutes/grid.417570.0
    23 https://www.grid.ac/institutes/grid.418019.5
    24 https://www.grid.ac/institutes/grid.418158.1
    25 https://www.grid.ac/institutes/grid.419513.b
    26 https://www.grid.ac/institutes/grid.423294.a
    27 https://www.grid.ac/institutes/grid.42505.36
    28 https://www.grid.ac/institutes/grid.430503.1
    29 https://www.grid.ac/institutes/grid.4367.6
    30 https://www.grid.ac/institutes/grid.477623.3
    31 https://www.grid.ac/institutes/grid.492893.d
    32 https://www.grid.ac/institutes/grid.492957.4
    33 https://www.grid.ac/institutes/grid.51462.34
    34 https://www.grid.ac/institutes/grid.5963.9
    35 https://www.grid.ac/institutes/grid.65499.37
    36 https://www.grid.ac/institutes/grid.66875.3a
    37 https://www.grid.ac/institutes/grid.67105.35
    38 schema:familyName Hurwitz
    39 schema:givenName Herbert I
    40 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68
    41 schema:sdDatePublished 2019-03-07T14:52
    42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    43 schema:sdPublisher N767e5403604743828cf7e6e568f10b2c
    44 sgo:license sg:explorer/license/
    45 sgo:sdDataset persons
    46 rdf:type schema:Person
    47 N2d3dc3ea35e14f6c9e885a56cd10444a schema:affiliation https://www.grid.ac/institutes/grid.189509.c
    48 sgo:isCurrent true
    49 rdf:type schema:OrganizationRole
    50 N767e5403604743828cf7e6e568f10b2c schema:name Springer Nature - SN SciGraph project
    51 rdf:type schema:Organization
    52 https://www.grid.ac/institutes/grid.10698.36 schema:Organization
    53 https://www.grid.ac/institutes/grid.14925.3b schema:Organization
    54 https://www.grid.ac/institutes/grid.16753.36 schema:Organization
    55 https://www.grid.ac/institutes/grid.189509.c schema:Organization
    56 https://www.grid.ac/institutes/grid.19006.3e schema:Organization
    57 https://www.grid.ac/institutes/grid.213910.8 schema:Organization
    58 https://www.grid.ac/institutes/grid.241116.1 schema:Organization
    59 https://www.grid.ac/institutes/grid.250942.8 schema:Organization
    60 https://www.grid.ac/institutes/grid.25879.31 schema:Organization
    61 https://www.grid.ac/institutes/grid.26009.3d schema:Organization
    62 https://www.grid.ac/institutes/grid.266102.1 schema:Organization
    63 https://www.grid.ac/institutes/grid.26790.3a schema:Organization
    64 https://www.grid.ac/institutes/grid.410513.2 schema:Organization
    65 https://www.grid.ac/institutes/grid.410569.f schema:Organization
    66 https://www.grid.ac/institutes/grid.410711.2 schema:Organization
    67 https://www.grid.ac/institutes/grid.411097.a schema:Organization
    68 https://www.grid.ac/institutes/grid.412807.8 schema:Organization
    69 https://www.grid.ac/institutes/grid.413696.f schema:Organization
    70 https://www.grid.ac/institutes/grid.414179.e schema:Organization
    71 https://www.grid.ac/institutes/grid.414316.5 schema:Organization
    72 https://www.grid.ac/institutes/grid.415302.1 schema:Organization
    73 https://www.grid.ac/institutes/grid.417570.0 schema:Organization
    74 https://www.grid.ac/institutes/grid.418019.5 schema:Organization
    75 https://www.grid.ac/institutes/grid.418158.1 schema:Organization
    76 https://www.grid.ac/institutes/grid.419513.b schema:Organization
    77 https://www.grid.ac/institutes/grid.423294.a schema:Organization
    78 https://www.grid.ac/institutes/grid.42505.36 schema:Organization
    79 https://www.grid.ac/institutes/grid.430503.1 schema:Organization
    80 https://www.grid.ac/institutes/grid.4367.6 schema:Organization
    81 https://www.grid.ac/institutes/grid.477623.3 schema:Organization
    82 https://www.grid.ac/institutes/grid.492893.d schema:Organization
    83 https://www.grid.ac/institutes/grid.492957.4 schema:Organization
    84 https://www.grid.ac/institutes/grid.51462.34 schema:Organization
    85 https://www.grid.ac/institutes/grid.5963.9 schema:Organization
    86 https://www.grid.ac/institutes/grid.65499.37 schema:Organization
    87 https://www.grid.ac/institutes/grid.66875.3a schema:Organization
    88 https://www.grid.ac/institutes/grid.67105.35 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...